Impact of Mavacamten Approval on Septal Reduction Therapy Rates in Hypertrophic Cardiomyopathy. [PDF]
Ibrahim R +9 more
europepmc +1 more source
Fibrosis and Myocardial Dysfunction in Hypertrophic Cardiomyopathy: A Sisyphean Association or a Challenge Worth Pursuing? [PDF]
Zegkos T, Gossios T, Parcharidou D.
europepmc +1 more source
A New Era in the Management of Hypertrophic Cardiomyopathy. [PDF]
Perez-Asensio A +5 more
europepmc +1 more source
Daniele Massera, Mark V. Sherrid
doaj +1 more source
Mechanisms of metabolic transition in hypertrophic cardiomyopathy. [PDF]
Tan C, Guo Z, Zhou J, Yuan W.
europepmc +1 more source
A review of the molecular mechanisms underlying the development and progression of cardiac remodeling [PDF]
et al,, Yee, Derek
core +1 more source
Revisiting the Genetics of Hypertrophic Cardiomyopathy: From Sarcomeres to Polygenic Modulation and Clinical Translation. [PDF]
Carella MC +13 more
europepmc +1 more source
Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy. [PDF]
Owens AT +8 more
europepmc +1 more source
Safety and efficacy of physical activity in hypertrophic cardiomyopathy patients: a systematic review and metanalysis. [PDF]
Borrelli F +5 more
europepmc +1 more source

